Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/4312
Title: | TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome | Authors: | Bećarević, Mirjana | Issue Date: | 1-Dec-2016 | Journal: | Rheumatology International | Abstract: | © 2016, Springer-Verlag Berlin Heidelberg. Antiphospholipid syndrome (APS) is characterized by thromboses and/or pregnancy losses. Laboratory criterion for the diagnosis of APS is the presence of antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I (aβ2gpI) and lupus anticoagulant). On the one hand, the latest classification criteria for the diagnosis of APS emphasized that thrombotic manifestations of the syndrome should be without any signs of an inflammatory process, while on the other hand, some recent reports have suggested that APS is a “pro-inflammatory state.” This article is focused on the importance of TNF-alpha and annexin A2 (anxA2) for patients with vascular (thrombotic) manifestations of the primary APS. The classic antithrombotic and antiplatelet therapy does not protect APS patients from the development of recurrent thrombosis. Therefore, an urgent need for the introduction of new therapeutic approaches in the treatment of APS patients is obvious. This review provides a rationale for the necessity for the use of immunomodulatory medications that could interfere with β2gpI binding to its receptor(s), such as anxA2, and/or inhibit TNF-alpha activity. | URI: | https://open.uns.ac.rs/handle/123456789/4312 | ISSN: | 1728172 | DOI: | 10.1007/s00296-016-3569-1 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
15
checked on May 10, 2024
Page view(s)
17
Last Week
7
7
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.